Novartis continues to have no plans to spin off its Sandoz unit, amid further moves towards autonomy for the generics and biosimilars division, including the recent carve-out of Sandoz’ manufacturing operations.
Novartis Emphasizes Message On Spinning Off Sandoz
Following Recent Carve-Out Of Sandoz Manufacturing Operations
Novartis has long championed the idea of making Sandoz an autonomous unit within the Swiss originator while stopping short of carving out the business altogether. Rumors continue to swirl around a potential deal, which was discussed during the recent virtual Meet Novartis Management event.